Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

ViraTherapeutics GmbH (ViraT)

Austrian based ViraTherapeutics GmbH (ViraT) was a privately held biopharmaceutical company developing promising innovative virus-based immunotherapeutics for the treatment of cancer. ViraT was founded in 2013 as a spin-out of the Medical University of Innsbruck by Prof. Dr. Dorothee von Laer, Head of the Division of Virology at the University. ViraT develops oncolytic cancer vaccines based on a chimeric virus derived from the Vesicular Stomatitis Virus (VSV), so called VSV-GP. Initially, ViraT received Pre-Seed financing funds from STARTUP.TIROL (previously CAST, Center for Academic Spin-offs Tyrol), Tyrol, and from the Austria Wirtschaftsservice GmbH (aws – the Austrian Government Promotional Bank). ViraT was funded by the Boehringer Ingelheim Venture Fund (BIVF), EMBL Ventures and the Empl foundation, as well as by the aws through its Venture-Capital-Initiative and Seedfinancing program and by the Austrian Research Promotion Agency (FFG) through several programs. The company currently has 19 employees. ViraT won the international life science business plan competition Best of Biotech 2012 and was awarded the second prize in the Science4Life venture cup 2013. ViraT has a collaboration with the Medical University of Innsbruck, which includes a team of scientists from the laboratory of Prof. von Laer and scientists of the Christian Doppler Laboratory for Viral Immunotherapy of Cancer at the university headed by Dr. Guido Wollmann. *

 

Period Start 2013-04-01 splitoff
  Group Boehringer Ingelheim (Group)
  Predecessor Medical University Innsbruck (MUI)
Product Industry cancer drug
Persons Person Schwer, Heinz (ViraTherapeutics 201705– CEO before Lanthio Pharma + Sloning BioTechnology CEO + Founder)
  Person 2 von Laer, Dorothee (ViraTherapeutics 201609 CEO + Scientific Founder)
     
Region Region Innsbruck
  Country Austria
  Street 20a Exlgasse
  City 6020 Innsbruck
  Tel +43-512-272061
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2018-09-13)
     
    * Document for �About Section�: ViraTherapeutics GmbH. (9/13/18). "Press Release: Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies". Ingelheim.
     
   
Record changed: 2018-09-13

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top